Hoffmann-La Roche

CO39303

NCT03072238

JCP022

Ipatasertib Plus Abiraterone Plus Prednisone / Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone / Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Ipatasertib

AKT inhibitor (p.o.)

Treatment Arms

o Experimental: Ipatasertib + Abiraterone

o Active Comparator: Placebo + Abiraterone